Close menu




Biotech

Photo credits: pixabay.com

Commented by Fabian Lorenz on March 27th, 2025 | 07:00 CET

Rocketing prices and takeover speculation! Steyr Motors, Evotec, and Defence Therapeutics!

  • Biotechnology
  • Biotech
  • Pharma
  • Defense

Steyr Motors is now riding not only the defense wave but also the takeover wave. After the announcement of a cooperation with a Rheinmetall subsidiary, the niche stock has become a shooting star. However, the price has also come back just as quickly. The Austrians now want to grow aggressively through acquisitions. Without takeover speculation, the share price of Defence Therapeutics has already risen by over 60%. The biotech company is still inexpensive, is making progress in monetization, and could become an acquisition candidate. Evotec is currently out of steam. Analysts see significant downside potential and a chance of a turnaround.

Read

Commented by Armin Schulz on March 25th, 2025 | 07:10 CET

Evotec, NetraMark, Novo Nordisk – From the lab to a golden digital future with artificial intelligence

  • Biotechnology
  • Biotech
  • Pharma
  • AI

The pharmaceutical industry is experiencing a revolution that is changing everything! Artificial intelligence is sweeping through laboratories and breaking with old habits. Algorithms scour billions of chemical structures in record time, uncovering hidden treasures of active ingredients. While years used to pass before a drug entered the testing phase, AI models are now picking up the pace. Heavyweights like AstraZeneca are in a neck-and-neck race with start-ups. Who will be the first to crack incurable diseases? The goal is to tailor therapies, revolutionize clinical studies, and save lives. Only those who use AI will remain competitive and be able to offer patients innovative drugs faster. The era of data-driven medicine has begun.

Read

Commented by Fabian Lorenz on March 25th, 2025 | 07:00 CET

Takeover speculation and buy recommendations: Buy Bayer, BioNTech, and BioNxt Solutions stock after a 150% rally?

  • Biotechnology
  • Biotech
  • Pharma

While takeover speculations are currently on pause for Evotec, they are gaining momentum for BioNxt Solutions. The Company aims to achieve significant milestones in the next 60 days on the road to marketing its lead product for treating multiple sclerosis and expanding into the billion-dollar anti-aging market. Even after the 150% rally, BioNxt shares are not expensive. The BioNTech share has corrected sharply in 2025. However, positive analyst comments could now herald a turnaround. Will the oncology pipeline lead to a breakthrough? On the other hand, Bayer is facing a significant defeat in USD. Further billion-dollar payments are looming. Analysts remain skeptical.

Read

Commented by Stefan Feulner on March 24th, 2025 | 07:20 CET

Bayer, Vidac Pharma, BioNTech – Setbacks and New Standards

  • Biotechnology
  • Biotech
  • Pharma

Glyphosate and no end in sight. Bayer's 2018 acquisition of US agricultural company Monsanto continues to develop into a billion-dollar grave, with a court again ruling against the Leverkusen-based company. Billions in revenue also disappeared from the books of vaccine manufacturer BioNTech after the COVID-19 pandemic subsided. In contrast, an innovative biopharmaceutical company is setting new standards in treating pediatric brain tumors.

Read

Commented by Armin Schulz on March 18th, 2025 | 07:00 CET

Bayer, Vidac Pharma, BioNTech – Making money with biotech and pharmaceutical innovations

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations

More and more investors are betting on companies that are leaving traditional therapeutic paths to rethink cancer, chronic inflammation, or nutritional issues. While some corporations struggle with their balance sheets due to mountains of debt and patent expirations, others are quietly developing technologies that crack the metabolic code of diseases. Whether anti-aging tests from saliva samples, mRNA-based cancer cocktails, or active ingredients that overcome the blood-brain barrier – the stock market rewards those who combine research success with strategic risk-taking. But which companies have what it takes to develop the blockbusters of tomorrow? Let's take a closer look at three companies.

Read

Commented by Juliane Zielonka on March 13th, 2025 | 07:00 CET

Big Pharma's billion-dollar markets under pressure – NetraMark as the key for Bayer and Novo Nordisk?

  • Healthcare
  • healthtech
  • Biotechnology
  • Pharma
  • AI
  • hightech

In 2025, the pharmaceutical market faces significant challenges, including rising costs and regulatory hurdles. In this environment, companies like NetraMark, Bayer, and Novo Nordisk could make a significant difference through innovative solutions and strategic partnerships. NetraMark, a Canadian HealthTech company, is revolutionizing clinical trials with AI technology, which could be particularly beneficial in the areas of research into active ingredients for the central nervous system and in oncology. These are currently the biggest dropouts in industry. NetraMark's technology could increase the efficiency of drug development and open up new opportunities for investors. Bayer is focusing on targeted therapies in precision oncology and has a promising drug in development that specifically targets an overarching mutation in various cancers. Novo Nordisk is cementing its reputation as an innovator in the fight against chronic obesity, particularly with its successor to the obesity drug CagriSema. The Phase III REDEFINE 2 study achieved its primary objective, although the results fell short of high expectations. A closer look is now warranted.

Read

Commented by Stefan Feulner on March 11th, 2025 | 07:30 CET

Bayer, BioNxt Solutions, Novo Nordisk – The pressure is on

  • Biotechnology
  • Biotech
  • Pharma

The biotech sector has started the new year with momentum, and the acquisition wave is heating up, as confirmed by Johnson & Johnson's acquisition of Intra-Cellular Therapies for USD 15 billion. The trend will likely continue as major pharmaceutical companies are under massive pressure to strengthen their portfolios. After all, drug patents worth over USD 200 billion will expire by the end of the decade. This will force the giants to make strategic acquisitions.

Read

Commented by Fabian Lorenz on March 11th, 2025 | 07:20 CET

Is a 100% rally on the horizon? Evotec, D-Wave, and AI pearl NetraMark

  • AI
  • hightech
  • Biotechnology
  • Biotech
  • computing

The sell-off in the tech sector continues at the beginning of the week. If sentiment changes, a 100% rally could start. At least, that is what analysts at D-Wave expect. Overall, analysts take a positive view of last year's quantum star. The development of the AI pearl NetraMark is also positive. With its NetraAI platform, the Company aims to revolutionize the development of drugs. The first customers are in place, and the latest study data is promising. Even in the current sell-off, the stock wants to go up. The positive news is currently evaporating at Evotec. The stock is threatening to fall below EUR 6. Are there further write-offs?

Read

Commented by Juliane Zielonka on March 7th, 2025 | 06:45 CET

Bayer, Vidac Pharma, Xiaomi: What matters now for your health

  • Biotechnology
  • Biotech
  • Pharma
  • Technology

Innovative solutions to improve the quality of life for millions of patients are the focus of a new generation of companies that are breaking new ground in research and technology. The German company Bayer is reporting impressive results for 2024 in its pharmaceutical division with Nubeqa™ for prostate cancer and plans to increase its sales to over EUR 2.5 billion in 2025. The biopharmaceutical company Vidac Pharma, currently in the clinical phase, specializes in the fight against tumors and is making progress in a Phase 2b study against actinic keratosis with the active ingredient VDA-1102. The Chinese tech company Xiaomi scores with smart health monitoring with products like the Watch S4. It also connects households and has expanded its Internet of Things ecosystem to millions of connected devices. These approaches – whether in medicine, cancer therapy, or health technology – offer progress for patients, users, and potential for investors who are focusing on sustainable growth. How are these companies shaping the future?

Read

Commented by André Will-Laudien on March 6th, 2025 | 07:00 CET

NETRAMARK HOLDINGS – Medical Revolution: How AI is Shortening Drug Approval by Years!

  • AI
  • hightech
  • Pharma
  • Biotechnology

Artificial Intelligence – now it is really taking off in the medical field! Among many other applications, big data and artificial intelligence (AI) applications are revolutionizing the optimization of clinical phases in drug approval by accelerating processes, reducing costs, and significantly increasing the success rate. AI can analyze large amounts of data from electronic health records, genomic data, and patient registries to identify suitable clinical trial participants more quickly and accurately. This significantly reduces recruitment time and improves accuracy. Machine learning can be used to analyze previous study results to develop more efficient study designs. Based on real-time data, adaptive study protocols enable dynamic adjustment of experimental conditions. The Canadian technology company NetraMark Holdings Inc. (WKN: A3D5X9 | ISIN: CA64119M1059 | Ticker symbol: AIAI) develops solutions for the pharmaceutical industry to utilize Generative Artificial Intelligence (Gen AI).

Read